ASND financial statements
The full income statement, balance sheet, and cash-flow statement for Ascendis Pharma A/S Ordinary Share (ASND), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 815M+107.1% | 393M+36.4% | 288M+436.1% | 53.8M+484.8% | 9.20M+16.1% | |
| 707M+104.7% | 346M+43.7% | 240M+485.8% | 41.0M+715.5% | 5.03M-36.5% | ||
| Cost of revenue | 107M+124.3% | 47.9M-0.3% | 48.0M+276.3% | 12.8M+206.2% | 4.17M | |
| Research & development | 344M+3.4% | 332M-25.7% | 447M+12.0% | 399M+14.0% | 350M+17.7% | |
| Operating income | -154M+48.9% | -302M+38.8% | -493M+16.6% | -591M-10.5% | -534M-41.8% | |
| Interest expense | 234M+116.1% | 108M+127.1% | 47.7M-10.2% | 53.1M+1047.4% | 4.63M-95.0% | |
| Pre-tax income | -241M+40.4% | -404M+21.2% | -513M+15.6% | -608M-33.8% | -454M+5.0% | |
| Income tax | 17.4M+232.1% | 5.24M-33.6% | 7.90M+39.7% | 5.65M+1402.3% | -434K-73.9% | |
| -258M+36.9% | -409M+21.4% | -521M+15.1% | -613M-35.1% | -454M+5.0% | ||
| Net income to common | -258M+36.9% | -409M+21.4% | -521M+15.1% | -613M-35.1% | -454M+5.0% | |
| -$4.25+39.8% | -$7.07+23.6% | -$9.25+15.4% | -$10.93-32.1% | -$8.28 | ||
| EPS (basic) | -$4.25+39.8% | -$7.07+23.6% | -$9.25+15.4% | -$10.93-32.1% | -$8.28 | |
| Weighted-avg shares (basic) | 60.6M+4.7% | 57.9M+2.9% | 56.3M+0.4% | 56.1M+2.4% | 54.8M+8.2% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 1.30B+17.7% | 1.11B+42.3% | 778M-21.0% | 984M+7.5% | 916M+1.0% | ||
| Cash & equivalents | 724M+24.0% | 584M+34.4% | 434M-8.5% | 474M-6.5% | 507M-29.2% | |
| Inventory | 354M+14.9% | 308M+33.3% | 231M+66.0% | 139M+62.6% | 85.7M | |
| 1.53B+24.4% | 1.23B+34.6% | 914M-21.3% | 1.16B-5.7% | 1.23B+2.7% | ||
| Property, plant & equipment | 172M+67.1% | 103M-15.9% | 122M-11.0% | 138M-3.9% | 143M+8.1% | |
| Total non-current assets | 227M+83.8% | 124M-9.0% | 136M-23.3% | 177M-44.1% | 317M+7.9% | |
| 1.26B+32.7% | 947M+16.2% | 815M+346.5% | 183M+60.2% | 114M+76.2% | ||
| Short-term & current debt | 504M+5.5% | 478M+6.1% | 451M+3534.2% | 12.4M+56.0% | 7.95M | |
| 1.72B+28.4% | 1.34B+24.7% | 1.08B+22.0% | 881M+285.3% | 229M+32.3% | ||
| Long-term debt | 453M+18.8% | 381M+54.3% | 247M-40.3% | 413M+271.2% | 111M | |
| -191M-73.5% | -110M+31.6% | -161M-157.4% | 281M-72.0% | 1.00B-2.3% | ||
| Total equity incl. non-controlling | -191M-73.5% | -110M+31.6% | -161M-157.4% | 281M-72.0% | 1.00B-2.3% | |
| Common shares issued | 62.0M+2.1% | 60.7M+5.2% | 57.7M+1.0% | 57.2M+0.4% | 56.9M+5.9% | |
| Shares outstanding (cover) | 62.0M+2.1% | 60.7M+5.2% | 57.7M+1.0% | 57.2M+0.4% | 56.9M+5.9% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Cash from operations | 61.0M+118.4% | -331M+34.4% | -505M+3.0% | -521M-5.5% | -494M-59.6% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 0.00-100.0% | 145M-1.5% | 147M-72.2% | 529M | 0.00 | |
| Long-term debt repaid | 24.8M+102.0% | 12.3M+8.9% | 11.3M+68.9% | 6.68M | 0.00 | |
| Common stock issued | 0.00-100.0% | 335M | 0.00 | 0.00-100.0% | 435M-34.2% | |
| Common stock repurchased | 19.7M | 0.00-100.0% | 115M+2.9% | 112M+336.5% | 25.6M | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 13.2B+58.2% | 8.36B+16.1% | 7.20B+3.5% | 6.95B-9.2% | 7.66B-14.6% | |
| P/S | 16.2×-23.6% | 21.2×-84.1% | 133.8×-82.3% | 755.8×-9.2% | 832.6×-26.4% | |
| P/B | — | — | 25.6×+270.1% | 6.9×-9.2% | 7.6×-12.5% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: ASND’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ASND filings on SEC EDGAR → Not investment advice.